Leading the Way in Life Science Technologies

GEN Exclusives

More »

Feature Articles

More »
Sep 15, 2010 (Vol. 30, No. 16)

Nigeria Eyes Biotech to Boost Healthcare

Developing Countries Evaluating Ability of Translational Technologies to Transform Status Quo

  • Future Challenges

    While stressing that the time to prepare to meet future health challenges is now, the Commissioner said that the current quarter of this century will be characterized by head-to-head competition in industries that offer high-paying jobs to their workers and bring prosperity and world prestige to their countries.

    These new technologies present both major challenges and opportunities for developing countries; however, there is the potential for serious disruptions in the architecture of the health system by these new technologies. Consequently some confusion may arise in the way investments should be made in the near term in order to optimize the integration of biotechnology in Nigerian healthcare delivery.

    The key to success will depend on cooperation between universities, hospitals, existing laboratories, private biotechnology companies, and research institutions both locally and abroad. The ability to create the necessary network of people and resources will be the final piece needed to complete this circle.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »